Minomic International Ltd

Minomic International Ltd, is a Sydney-based cancer diagnostics that has developed MiCheck Prostate, an innovative blood test designed to assess the risk of clinically significant prostate cancer, marking a significant advancement in cancer diagnostics. Clinical studies have shown MiCheck Prostate achieves a sensitivity of 95% with superior specificity surpassing existing testing methods. MiCheck Prostate delivers enhanced reliability in early cancer detection by: - reducing false positives by up to 50%, minimizing unnecessary biopsies and resulting in substantial healthcare cost savings. - providing practitioners with better-quality information to support biopsy decisions. The test is commercially available in the USA through its...

Diagnostics biomarkers proteomics,detection of prostate cancer,immunology,psa test,oncology,clinical antibody program,diagnostic imaging for cancer,and therapeutics for prostate and other cancers

Minomic international ltd operates in the Biotechnology research industry.

Minomic international ltd's revenue is 11m - 100m

Minomic international ltd has 11 - 50 employees.